

ASX/Media Release

### **2020 Annual General Meeting and Key Dates**

Immutep Limited (ASX: IMM; NASDAQ: IMMP) advises that it intends to hold its 2020 Annual General Meeting, (AGM) on Tuesday, 27 October 2020 commencing at 10.30am (AEDT).

The Company further advises that the closing time and date for receipt of director nominations for candidates other than those recommended by the Board is 5:00pm, Tuesday 22 September 2020.

#### **Virtual AGM**

Due to the ongoing impact of the COVID-19 pandemic and in consideration of the safety of shareholders, employees and the broader community, the Company will hold the AGM virtually rather than at a physical location this year.

Shareholders will be provided with more information on how to participate in the AGM in the Notice of the Meeting which will be released later this month on the Company's ASX market announcements page.

#### **Notice of Meeting**

In accordance with temporary modifications to the *Corporations Act* under the Corporations (Coronavirus Economic Response) Determination (No.1) 2020, the Company will not send hard copies of the Notice of Meeting to shareholders.

Shareholders who normally receive a hard copy of AGM related documents are encouraged to provide their email address to the share registry, Boardroom Limited at [enquiries@boardroomlimited.com.au](mailto:enquiries@boardroomlimited.com.au) before Thursday 17<sup>th</sup> September 2020 to enable the Company to send the 2020 AGM related documentation electronically.

Shareholders can also elect to receive future correspondence from the Company electronically by informing Boardroom Limited of this request via the above email address or by changing their communications election at <https://www.investorserve.com.au/>. If you have not yet registered, you will need your shareholder information including SRN/HIN details.

This announcement was authorised for release by the board of Immutep Limited.

Further information can be found on the Company's website [www.immutep.com](http://www.immutep.com) or by contacting:

#### **Australian Investors/Media:**

Catherine Strong, Citadel-MAGNUS  
+61 (0)406 759 268; [cstrong@citadelmagnus.com](mailto:cstrong@citadelmagnus.com)

#### **U.S. Media:**

Tim McCarthy, LifeSci Advisors  
+1 (212) 915.2564; [tim@lifesciadvisors.com](mailto:tim@lifesciadvisors.com)

## About Immutep

Immutep is a globally active biotechnology company that is a leader in the development of LAG-3 related immunotherapeutic products for the treatment of cancer and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Immutep is listed on the Australian Securities Exchange (IMM) and on the NASDAQ (IMMP) in the United States.

Immutep's current lead product candidate is efitlagimod alpha ("efti" or "IMP321"), a soluble LAG-3 protein (LAG-3lg) based on the LAG-3 immune control mechanism. This mechanism plays a vital role in the regulation of the T cell immune response. Efti is currently in a Phase IIb clinical trial as a chemoimmunotherapy for metastatic breast cancer termed AIPAC (clinicaltrials.gov identifier NCT02614833); a Phase II clinical trial being conducted in collaboration with Merck & Co., Inc., Kenilworth, NJ, USA (known as "MSD" outside the United States and Canada) referred to as TACTI-002 to evaluate a combination of efti with KEYTRUDA® (pembrolizumab) in several different solid tumours (clinicaltrials.gov identifier NCT03625323); a Phase I clinical trial being conducted in collaboration with Merck KGaA, Darmstadt, Germany and Pfizer Inc. referred to as INSIGHT-004 to evaluate a combination of efti with avelumab (clinicaltrials.gov identifier NCT03252938); and a Phase I combination therapy trial in metastatic melanoma termed TACTI-mel (clinicaltrials.gov identifier NCT02676869).

Additional LAG-3 products, including antibodies, for immune response modulation in autoimmunity and cancer are being developed by Immutep's large pharmaceutical partners. Immutep is also developing an agonist of LAG-3 (IMP761) for autoimmune disease.